## WEDNESDAY, 21<sup>st</sup> JUNE 2017 COMMENCING 09:30 AM AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST LLANEDEYRN, CARDIFF, CF23 9XF

## **AGENDA**

**Enclosure** 

- 1. Welcome and introduction
- 2. Apologies
- 3. **Declarations of interest**
- 4. Minutes of previous meeting

1/AWMSG/0617

To protect commercial confidentiality the meeting will close to the public and the following appraisal will be held in private

Appraisal 1: Full Submission (WPAS)
 Ivacaftor (Kalydeco®) for the treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CFTR gene

**2**/AWMSG/0617 Appendices

## The meeting will now re-open to the public

- 6. Chairman's report (verbal update)
- 7. National Prescribing Indicators 2016–2017 Analysis of Prescribing Data to December 2016

3/AWMSG/0617

8. All Wales Multidisciplinary Medicines Reconciliation Policy

4/AWMSG/0617

9. Appraisal 2: Full Submission
Aviptadil phentolamine (Invicorp®) for symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasulogenic, psychogenic, or mixed aetiology

**5**/AWMSG/0617 Appendices

10. Date of next meeting – 19th July 2017 in Cardiff